Radiation Therapy in Treating Patients With Stage I or Stage II Non-Small Cell Lung Cancer
| Status: | Active, not recruiting |
|---|---|
| Conditions: | Lung Cancer, Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | 18 - 120 |
| Updated: | 3/24/2019 |
| Start Date: | September 12, 2008 |
| End Date: | April 15, 2021 |
A Phase II Randomized Study of 2 Stereotactic Body Radiation Therapy (SBRT) Regimens for Medically Inoperable Patients With Node Negative, Peripheral Non-Small Cell Lung Cancer
RATIONALE: Stereotactic body radiation therapy may be able to send x-rays directly to the
tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation
therapy is more effective in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy
regimens and to see how well they work in treating patients with stage I or stage II
non-small cell lung cancer.
tumor and cause less damage to normal tissue. It is not yet known which regimen of radiation
therapy is more effective in treating patients with non-small cell lung cancer.
PURPOSE: This randomized phase II trial is studying the side effects of two radiation therapy
regimens and to see how well they work in treating patients with stage I or stage II
non-small cell lung cancer.
OBJECTIVES:
Primary
- To compare the incidence of toxicity with two established stereotactic body radiotherapy
(SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell
lung cancer.
Secondary
- To compare quality of life, patterns of failure, disease-free survival, and overall
survival of these patients after treatment with one of two established SBRT regimens.
- To correlate outcomes and toxicities with imaging and patient and tumor biomarkers.
OUTLINE: Patients are stratified according to Karnofsky performance status and treatment
center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
- Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires
Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA
and immunoblotting.
After completion of study treatment, patients are followed for 5 years.
Primary
- To compare the incidence of toxicity with two established stereotactic body radiotherapy
(SBRT) regimens in patients with node-negative, peripheral stage I or II non-small cell
lung cancer.
Secondary
- To compare quality of life, patterns of failure, disease-free survival, and overall
survival of these patients after treatment with one of two established SBRT regimens.
- To correlate outcomes and toxicities with imaging and patient and tumor biomarkers.
OUTLINE: Patients are stratified according to Karnofsky performance status and treatment
center. Patients are randomized to 1 of 2 treatment arms.
- Arm I: Patients undergo 1 high-dose fraction of stereotactic body radiotherapy (SBRT).
- Arm II: Patients undergo 3 high-dose fractions (approximately 1 week apart) of SBRT.
Quality of life is assessed periodically by the EORTC QLQ-C30 and -LC13 questionnaires
Blood and tissue samples may be collected periodically and examined for biomarkers via ELISA
and immunoblotting.
After completion of study treatment, patients are followed for 5 years.
Inclusion Criteria:
- Histologically confirmed non-small cell lung cancer
- T1-T2, N0 disease measuring ≤ 5 cm( T3 tumor based on chest wall involvement is
Excluded)
- Surgically resectable primary disease, however patient evaluated by thoracic
oncologist and deemed medically inoperable OR patient refuses surgical resection
- Age >= 18
Exclusion Criteria:
- Prior thoracic radiation therapy
- T2 or T3 tumor greater than 5 cm or T3 tumor based on chest wall involvement
- Node positive or metastatic disease
- Tumor location within the zone of the proximal bronchial tree. The proximal bronchial
tree is defined as the carina, right and left main bronchi, right and left upper lobe
bronchi, bronchus intermedius, right middle lobe bronchus, lingular bronchus, and
right and left lower lobe bronchi. The zone of the proximal bronchial tree is defined
as a volume 2cm in all directions around the proximal bronchial tree.
- No other conditions deemed by the PI or associates to make the patient ineligible for
protocol investigations, procedures, and high-dose external beam radiotherapy (e.g.,
unable to lie still and breathe reproducibly)
- Pregnant or unwilling to use adequate contraception
We found this trial at
3
sites
Roswell Park Cancer Institute Welcome to Roswell Park Cancer Institute (RPCI), America's first cancer center...
Click here to add this to my saved trials
Cleveland Clinic Cleveland Clinic is committed to principles as presented in the United Nations Global...
Click here to add this to my saved trials
Click here to add this to my saved trials